In the after-market trading session on Thursday, Evelo Biosciences, Inc. (EVLO) experienced a significant surge, with its price reaching $0.31, reflecting a remarkable change percentage of 273.94%. During regular trading hours, as the stock closed at $0.0829, marking a decrease of 15.92% from the previous day’s closing price.
Clinical Program Updates and Future Outlook
Evelo Biosciences recently provided updates on its clinical programs, focusing on two key trials: EDP1815 Phase 2 in Atopic Dermatitis and EDP2939 Phase 1/2 in Psoriasis.
Regarding the EDP1815 trial for Atopic Dermatitis, the fourth cohort of the EDP1815-207 trial did not meet the primary endpoint of achieving a 50% improvement from baseline in the Eczema Area and Severity Index (EASI) score. However, a response of EASI-50 or greater was observed in 37.9% of patients receiving EDP1815, compared to 44.7% on placebo at week 16. The faster release capsule of EDP1815 was generally well tolerated.
As for the EDP2939 trial for Psoriasis, enrollment has been completed for the Phase 2 portion of the study, which is evaluating extracellular vesicles in moderate psoriasis. Topline data from this phase is expected to be reported early in the fourth quarter of 2023. The safety review committee noted no notable safety or tolerability concerns based on the data from completed cohorts 1 and 2 of the Phase 1 healthy volunteer portion of the study.
Financial Snapshot and Market Performance
Evelo Biosciences, Inc. has a year high of $3.29 and a year low of $0.02, with a current market capitalization of $9.28 million. The stock’s 50-day moving average price stands at $0.14, while the 200-day moving average price is $1.15. The company is listed on NASDAQ, and its trading volume has reached 18.68 million shares, surpassing the average volume of 4.13 million shares.
Analyzing Stock Performance
EVLO stock has faced significant downward pressure in recent periods, with notable declines across various time frames. Over the past one day, five days, one month, and three months, the stock has experienced negative price changes of -15.92%, -24.01%, -41.45%, and -73.68%, respectively. Looking at the longer-term trend, the stock has faced a substantial decline of -95.52% over the past six months. Furthermore, the year-to-date and one-year price changes have recorded significant drops of -94.72% and -95.45%, respectively. Over the span of three years, five years, and ten years, the stock has seen drastic decreases of -97.84%, -99.27%, and -99.48%, respectively, indicating a substantial downward trend in the stock’s value.
Evelo Biosciences, Inc.’s financial data for the period ending December 31, 2022, reveals a negative net income of $114.5 million, resulting in an earnings per share (EPS) of -$1.31. The company reported a high debt ratio of 1.21, while its return on equity (ROE) was recorded at -34.92%. The operating cash flow per share and free cash flow per share for the trailing twelve months (TTM) were -$0.83 and -$0.84, respectively.